Guangdong Hybribio Biotech Co Ltd Total Assets
Guangdong Hybribio Biotech Co Ltd total assets. Based on the latest financial reports, Guangdong Hybribio Biotech Co Ltd (300639) holds total assets worth CN¥4.20 Billion CNY (≈ $614.42 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Guangdong Hybribio Biotech Co Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Guangdong Hybribio Biotech Co Ltd (2012–2025)
Total assets of Guangdong Hybribio Biotech Co Ltd from 2012 to 2025. This chart illustrates how Guangdong Hybribio Biotech Co Ltd's total assets have evolved over time, based on quarterly financial data. See today's stock price for Guangdong Hybribio Biotech Co Ltd for real-time trading data and today's change.
Guangdong Hybribio Biotech Co Ltd - Asset Composition Analysis
Guangdong Hybribio Biotech Co Ltd Total Assets Breakdown (December 2025)
Guangdong Hybribio Biotech Co Ltd total assets breakdown as of December 2025. Guangdong Hybribio Biotech Co Ltd's total assets of CN¥4.20 Billion consist of 45.7% current assets and 54.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 19.3% |
| Accounts Receivable | CN¥696.97 Million | 16.8% |
| Inventory | CN¥61.86 Million | 1.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥283.16 Million | 6.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Guangdong Hybribio Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Guangdong Hybribio Biotech Co Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guangdong Hybribio Biotech Co Ltd's current assets represent 45.7% of total assets in 2025, a decrease from 61.8% in 2012.
- Cash Position: Cash and equivalents constituted 19.3% of total assets in 2025, up from 14.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 22.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 16.8% of total assets.
Guangdong Hybribio Biotech Co Ltd Competitors by Total Assets
Key competitors of Guangdong Hybribio Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Diagnósticos da América S.A
SA:DASA3
|
Brazil | R$21.10 Billion |
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.52 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.66 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
Guangdong Hybribio Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.39 | 4.99 | 3.59 |
| Quick Ratio | 5.17 | 4.80 | 3.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.38 Billion | CN¥1.64 Billion | CN¥1.89 Billion |
Guangdong Hybribio Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Guangdong Hybribio Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.99 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -10.3% |
| Total Assets | CN¥4.15 Billion |
| Market Capitalization | $539.24 Million USD |
Valuation Analysis
Below Book Valuation: The market values Guangdong Hybribio Biotech Co Ltd's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Guangdong Hybribio Biotech Co Ltd's assets decreased by 10.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Guangdong Hybribio Biotech Co Ltd (2012–2025)
The table below shows the annual total assets of Guangdong Hybribio Biotech Co Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥4.15 Billion ≈ $606.93 Million |
-10.28% |
| 2024-12-31 | CN¥4.62 Billion ≈ $676.49 Million |
-19.26% |
| 2023-12-31 | CN¥5.73 Billion ≈ $837.86 Million |
-14.94% |
| 2022-12-31 | CN¥6.73 Billion ≈ $984.98 Million |
+59.08% |
| 2021-12-31 | CN¥4.23 Billion ≈ $619.18 Million |
+48.11% |
| 2020-12-31 | CN¥2.86 Billion ≈ $418.06 Million |
+120.28% |
| 2019-12-31 | CN¥1.30 Billion ≈ $189.79 Million |
+9.15% |
| 2018-12-31 | CN¥1.19 Billion ≈ $173.88 Million |
+11.09% |
| 2017-12-31 | CN¥1.07 Billion ≈ $156.52 Million |
+84.69% |
| 2016-12-31 | CN¥579.15 Million ≈ $84.75 Million |
+17.28% |
| 2015-12-31 | CN¥493.83 Million ≈ $72.26 Million |
+28.05% |
| 2014-12-31 | CN¥385.66 Million ≈ $56.43 Million |
+42.30% |
| 2013-12-31 | CN¥271.02 Million ≈ $39.66 Million |
+60.13% |
| 2012-12-31 | CN¥169.25 Million ≈ $24.77 Million |
-- |
About Guangdong Hybribio Biotech Co Ltd
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-tim… Read more